Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 1928

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 9C
Chunk 1928
---
, and persons performing similar functions.
We intend to disclose future amendments to such policy, or any waivers of its requirements, applicable to any principal executive
officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions or our
directors on our website identified above or in a Current Report on Form 8-K that we would file with the SEC.

Our
directors and executive officers may adopt written plans, known as Rule 10b5-1 plans, in which they will contract with a broker
to buy or sell shares of our Common Stock on a periodic basis. Under a Rule 10b5-1 plan, a broker executes trades pursuant to
parameters established by the director or officer when entering into the plan, without further direction from them. The director
or officer may amend a Rule 10b5-1 plan in some circumstances and may terminate a plan at any time. Our directors and executive
officers also may buy or sell additional shares outside of a Rule 10b5-1 plan when they are not in possession of material non-public
information subject to compliance with the terms of our insider trading policy. Prior to 180 days after the date of the pricing
of our IPO, subject to early termination, the sale of any shares under such plans would be prohibited by the lock-up agreement
that the director or officer has entered into with the underwriters.

Item
11. Executive Compensation.

Our
named executive officers for 2024 were Mr. Francis Knuettel II, our Chief Executive Officer and President, Chief Financial Officer,
Treasurer and Secretary, and Dr. Eric Lang, our Chief Medical Officer. Mr. Knuettel was first appointed in June 2022, and Dr.
Lang was first appointed in May 2023.

Summary
Compensation Table

The
following table provides information regarding the compensation of our named executive officers during the years ended December
31, 2024 and 2023.

    Name and Principal Position 
    Year  
    Salary  
    Bonus  
    Option Awards  
    Non-Equity Incentive Plan Compensation  
    All Other Compensation  
    Total 

    Francis Knuettel II 
     2024  
    $424,923  
    $56,666  
    $361,833  
    $—  
    $—  
    $843,422 

    Chief Executive and Chief Financial Officer 
     2023